COLLECTION SPONSOR
We are grateful for the support of our Sponsor Alnylam Pharmaceuticals, Inc. As always, Nature carries sole responsibility for all editorial content.
Top of pageProduced with support from: Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection, which is the leading cause of hospitalization in infants in the U.S. The company�s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. Alnylam is honored to be the �emerging/mid-cap� company recipient of the 2006 James D. Watson Helix Award, the biotechnology industry�s award for outstanding achievement. For more information, visit www.alnylam.com.
